Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Stem cell gel could speed burn healing in new trial

NCT ID NCT07580755

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a gel made from umbilical cord stem cells can help heal severe burns faster and more safely. About 90 adults with burns covering less than 30% of their body will receive either a low-dose, high-dose, or placebo gel on their donor skin site. The main goal is to see how quickly the skin grows back and fully heals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntary participation and signing of the informed consent form; 2. Burn patients, subjects requiring autologous skin grafting; 3. Age 18 to 65 years old, gender not restricted; 4. During this clinical study, single person, single donor skin area (lateral thigh or trunk) treatment; 5. Skin burn area \< 30% of total body surface area (TBSA); 6. The donor skin area is the first time for donation, and the donor skin area is medium-thick skin (thickness approximately 0.4mm); 7. The area of the excised skin flap ≥ 90 cm2; 8. Able to cooperate with this study protocol and accept regular postoperative follow-up visits. Exclusion Criteria: 1. Those allergic to sodium alginate (gel component); 2. Electric shock injuries, chemical burns, radiation injuries or combined with other traumas; 3. Subjects with severe systemic diseases (judged by the researchers); 4. Subjects with uncontrolled hypertension or diabetes (judged by the researchers); 5. Pregnant or lactating women; 6. Subjects whose condition may affect the study assessment or require the concurrent use of medical treatments that may affect the efficacy assessment; 7. Subjects with acute or chronic kidney diseases, renal failure or serum creatinine level = 1.5 times the upper limit of normal value; 8. Subjects with acute or chronic liver diseases, total bilirubin, alanine aminotransferase, aspartate aminotransferase = 2.0 times the upper limit of normal value; 9. Subjects with a history of malignant tumors; 10. Subjects who have participated in other clinical studies for less than 3 months; 11. Subjects with mental disorders and without self-awareness, unable to express clearly; 12. Subjects using immunosuppressants and those who have been using corticosteroids for a long time (more than 1 month) (excluding local application); 13. Subjects with infectious diseases (any one of the four items positive in the test); 14. Subjects with other severe systemic diseases; 15. Other subjects that the researchers consider not eligible for inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Burn injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Xinxiang Medical College

    RECRUITING

    Xinxiang, Henan, 453000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.